Apixaban's Mechanism on Factor Xa

How does apixaban inhibit factor Xa in free and clot-bound states?

Apixaban is a small-molecule, reversible, direct inhibitor that binds the active site of factor Xa (FXa) — it doesn't need antithrombin as a cofactor, unlike heparins or fondaparinux. The same active-site binding works whether FXa is free in plasma or assembled into prothrombinase on a platelet/phospholipid surface or sequestered within a thrombus, which is the property that distinguishes the direct FXa inhibitors from antithrombin-dependent ones.

Free FXa

Luettgen et al. measured a Ki of 0.25 nM at 37 °C, an association rate constant (k_on) of ~20 µM⁻¹ s⁻¹, and a dissociation half-life of 1–2 minutes — fast, tight, reversible occupancy of the active site (Luettgen et al. 2011). Selectivity for FXa over other coagulation serine proteases is >30,000-fold (Wong et al. 2011).

Prothrombinase-bound FXa

When FXa is assembled with factor Va on a phospholipid surface (the prothrombinase complex that actually generates thrombin in vivo), apixaban still binds with high affinity but kinetics shift: Ki rises modestly to 0.62 nM and k_on drops to ~12 µM⁻¹ s⁻¹. With prothrombin also engaged (the catalytically loaded prothrombinase·prothrombin complex), Ki is 1.7 nM and k_on ~4 µM⁻¹ s⁻¹. The inhibition is mixed-type under physiological conditions, and the same mechanism and kinetics hold up in prothrombin-depleted human plasma (Luettgen et al. 2011).

Clot-bound FXa

FXa generated within a forming thrombus remains catalytically active and is largely shielded from antithrombin-dependent inhibitors. Because apixaban is small and acts directly on the active site, it reaches and inhibits this clot-associated pool: Wong et al. report that apixaban inhibits free, prothrombinase-bound, and clot-bound FXa in vitro (Wong et al. 2011), and Jiang et al. demonstrated the clot-bound activity specifically in human plasma clot assays (Jiang et al. 2009).

The practical consequence: because thrombin generation by prothrombinase is the rate-limiting amplifier of coagulation, blocking FXa in both pools blunts thrombin burst without directly affecting platelet aggregation — apixaban's antiplatelet effect is indirect, via reduced thrombin (Wong et al. 2011).

A caveat on the kinetic numbers: the Ki values above are from Luettgen et al.'s purified-system + plasma assays. An earlier discovery-stage paper cites a Ki of 0.08 nM for human FXa (Wong et al. 2011), reflecting differences in assay conditions (substrate, ionic strength, temperature) rather than a substantive disagreement.